
Quiver Bioscience Secures Strategic Investment from the Porta Family to Advance UBE3A ASO Therapy for Dup15q Syndrome
Quiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q Syndrome Quiver Bioscience a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system (CNS) disorders, today announced…












